Innovative microbial strategies in atopic dermatitis
- PMID: 40771816
- PMCID: PMC12325183
- DOI: 10.3389/fimmu.2025.1605434
Innovative microbial strategies in atopic dermatitis
Abstract
Atopic dermatitis (AD) is characterized by chronic and recurrent itching with a high burden of disability-adjusted life years (DALYs, a measure of overall disease burden). Traditional treatments mainly include corticosteroids, which have a good effect on controlling inflammation but adverse side effects. Recently, advancements in understanding the pathogenesis of AD have led to the emergence of a variety of novel therapeutic approaches, such as microbiome manipulation, offering renewed hope for more effective management of this condition. These strategies are particularly promising for mild-to-moderate AD, where dysbiosis and immune imbalance (e.g., Th2 skewing) are key drivers, though some approaches (e.g., fecal microbiota transplantation) are being explored for refractory cases. It has been shown that microbiome manipulation has the potential to improve disease states and regulates the balance of the inflammatory system in a variety of ways. Various approaches have been preclinically and clinically tested, including probiotics (and multiple co-applications), prebiotics, postbiotics, unmethylated CpG motifs, fecal microbiota transplantation, herbal fermentation technology with microorganisms and phage. In this review, we discuss these microbiome manipulation methods and emphasizes the potential of microbiome-based interventions to modulate Th1/Th2 balance with fewer side effects, ultimately leading to control of inflammation in AD. Further translational research in this field is needed to integrate when we apply this therapy and the capability for disease treatment and prevention.
Keywords: CpG-ODNs; atopic dermatitis; fecal microbiota transplantation; herbal fermentation technology; microbial strategies; postbiotics; prebiotics; probiotics.
Copyright © 2025 Ma, Fang, Hu, Li, Zeng, Chen, Li, Meng, Yang, Zhang, Ji, Liao, Chen and Wu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Gut microbiome-based interventions for the management of obesity in children and adolescents aged up to 19 years.Cochrane Database Syst Rev. 2025 Jul 10;7(7):CD015875. doi: 10.1002/14651858.CD015875. Cochrane Database Syst Rev. 2025. PMID: 40637175 Review.
-
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2. Cochrane Database Syst Rev. 2022. PMID: 36126902 Free PMC article.
-
Microbiome-Based Products: Therapeutic Potential for Inflammatory Skin Diseases.Int J Mol Sci. 2025 Jul 14;26(14):6745. doi: 10.3390/ijms26146745. Int J Mol Sci. 2025. PMID: 40724992 Free PMC article. Review.
-
Oral Postbiotics as a Therapeutic Strategy for Atopic Dermatitis: A Systematic Review of Randomized Controlled Trials.J Am Nutr Assoc. 2024 Feb;43(2):139-146. doi: 10.1080/27697061.2023.2232021. Epub 2023 Jul 17. J Am Nutr Assoc. 2024. PMID: 37459239
-
Kidney-Gut Axis in Chronic Kidney Disease: Therapeutic Perspectives from Microbiota Modulation and Nutrition.Nutrients. 2025 Jun 9;17(12):1961. doi: 10.3390/nu17121961. Nutrients. 2025. PMID: 40573072 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources